Research by Isabelle Gagnon-Arpin

(Displaying 1 to 14 of 14)
Will Canada be able to keep up with Canada’s growing eye needs? This impact paper quantifies the value of ophthalmology from a population health, health care system, and broader...
The Conference Board of Canada | 37 pages | November 2020 | by Isabelle Gagnon-Arpin, Nicholas Moroz, Monika Slovinec D’Angelo, Zhenzhen Ye
This impact paper identifies the contribution that various health care cost drivers, including COVID-19, have on projections for health care expenditures in Canada.
The Conference Board of Canada | 49 pages | October 2020 | by Isabelle Gagnon-Arpin, Greg Hermus
Ce document évalue l’impact des divers facteurs de croissance des coûts des soins de santé, dont la COVID-19, sur les projections des dépenses de santé au Canada.
The Conference Board of Canada | 55 pages | October 2020 | by Isabelle Gagnon-Arpin, Greg Hermus
The retail price paid for pharmaceuticals is a result of several different inputs, few of which are well understood by consumers. Pharmacy mark-ups are especially elusive, as they...
The Conference Board of Canada | Recorded Webinar | October 2018 | by Isabelle Gagnon-Arpin
This briefing explores the inputs and costs that are reflected in the final retail cost of pharmaceuticals, sheds light on how pharmacy markups are determined, and discusses key...
The Conference Board of Canada | 43 pages | October 2018 | by Isabelle Gagnon-Arpin, Ruben Vroegop, Thy Dinh
Cette note de recherche examine les intrants et les coûts qui se reflètent dans le prix de détail final des produits pharmaceutiques, aide à mieux comprendre les marges bénéficiaires...
Le Conference Board du Canada | 47 pages | October 2018 | by Isabelle Gagnon-Arpin, Ruben Vroegop, Thy Dinh
This was a free webinar.Cardiovascular disease (CVD) prevalence incurs significant costs to governments and society in the form of hospitalizations, disease management, and lost...
The Conference Board of Canada | Recorded Webinar | July 2017 | by Isabelle Gagnon-Arpin
The scope of pharmacy services has expanded in many Canadian jurisdictions in recent years, with each province and territory taking a different approach to optimize these changes...
The Conference Board of Canada | Recorded Webinar | July 2017 | by Isabelle Gagnon-Arpin
This report examines the savings generated by increasing access to a new medication category—proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i)—which effectively...
The Conference Board of Canada | 69 pages | April 2017 | by Isabelle Gagnon-Arpin, Greg Sutherland
Ce rapport examine les économies générées par le recours accru à une nouvelle catégorie de médicaments – les inhibiteurs de la proprotéine convertase subtilisine/kexine de type...
Le Conference Board du Canada | 75 pages | April 2017 | by Isabelle Gagnon-Arpin, Greg Sutherland
The scope of pharmacy services has expanded in many Canadian jurisdictions in recent years. This report estimates the health and economic impact of three community pharmacy services...
The Conference Board of Canada | 106 pages | April 2017 | by Isabelle Gagnon-Arpin, Alexandru Dobrescu, Greg Sutherland, Carole Stonebridge, Thy Dinh
Ces dernières années, l’éventail des services dispensés en pharmacie a été élargi dans un grand nombre d’administrations provinciales et territoriales du Canada. Ce rapport présente...
Le Conference Board du Canada | 111 pages | April 2017 | by Isabelle Gagnon-Arpin, Alexandru Dobrescu, Greg Sutherland, Carole Stonebridge, Thy Dinh
This report examines the economic impact of switching three categories of drugs from prescription to over the counter, and the impact on stakeholders including private insurers,...
The Conference Board of Canada | 82 pages | March 2017 | by Isabelle Gagnon-Arpin
Le présent rapport examine les incidences économiques de la mise en vente libre de trois catégories de médicaments et ses effets sur les intervenants, à savoir les assureurs privés,...
Le Conference Board du Canada | 85 pages | March 2017 | by Isabelle Gagnon-Arpin
(Displaying 1 to 14 of 14)